Ignite Creation Date:
2024-05-06 @ 3:14 PM
Last Modification Date:
2024-10-26 @ 1:45 PM
Study NCT ID:
NCT04566952
Status:
UNKNOWN
Last Update Posted:
2020-10-30
First Post:
2020-09-24
Brief Title:
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
Sponsor:
Xiaoxiang Chen
Organization:
Jiangsu Cancer Institute Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| BRCA2 Mutation |
| Ovarian Cancer |
| Ovarian and Fallopian Tube Cysts and Neoplasms |
| Neoplasms by Site |
| Neoplasms |
| Genital Neoplasms Female |
| Urogenital Neoplasms |
| Neoplasms Glandular and Epithelial |
| Neoplasms by Histologic Type |
| Carcinoma Ovarian Epithelial |
| Ovarian Diseases |
| Adnexal Diseases |
| Genital Diseases Female |
| Carcinoma |
| Anlotinib |
| PARP Inhibitors |
| BRCA1 Mutation |
| Angiogenesis |
| Antineoplastic Agents |